Comparing the Efficacy and Safety of Pembrolizumab (Anti-PD1) vs. Chemotherapy in Positive-Tumor Proportion Score, Non-Small-Cell Lung Cancer Patients: A Meta-Analysis
Abstract – Lung cancer, typically caused by smoking, is one of the most common cancers. Both immunotherapy and chemotherapy have been suggested as ways to help treat lung cancer. In this meta-analysis, we extracted data from 9 clinical trials on the efficacy and safety of the immunotherapeutic drug pembrolizumab compared to chemotherapy. Efficacy was measured utilizing overall survival and progression-free survival rates while safety was evaluated using the percentage of adverse effects and immune-mediated effects. Pembrolizumab was found to be more effective than chemotherapy at increasing overall survival and progression-free survival rates. Pembrolizumab combined with chemotherapy did not increase overall survival rates when compared with chemotherapy only; however, it did increase progression-free survival rates. Pembrolizumab was found to be just as safe as chemotherapy overall, but it had more immune-mediated effects.